Endocyte, Inc.
Nov 3, 2011
PDF
Add to Briefcase

Endocyte Announces Third Quarter 2011 Earnings Conference Call

WEST LAFAYETTE, Ind., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, November 10, 2011, at 4:30 PM Eastern Standard Time to discuss its third quarter 2011 financial results and provide an operational update.

Investors and the general public are invited to listen to a live webcast of the call in the Investor Relations section of the Company's website at www.endocyte.com or by dialing (877) 845-0711 (US/Canada) or (760) 298-5081 (International).

A replay of the call will be available beginning at 6:30 PM EST on November 10, 2011, until Midnight EST on November 17, 2011. To access the replay, please dial (855) 859-2056 (US/Canada) or (404) 537-3406 (International) and reference the conference ID 24655768. Additionally, the webcast will be recorded and available on the Company's website following the call.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

During the course of this presentation, we will make forward-looking statements regarding future events and our future performance. The words "believe", "anticipate", "expect", "estimate", "intend", "plan", "may", "will" and other similar expressions generally identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements entail various significant risks and uncertainties that could cause our actual results to differ materially from those expressed in such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not intend to update any of the information contained in any forward-looking statement, except as required by law. Please see the section entitled "Risk Factors" in the most recent reports and other documents we file with the SEC for a more detailed description of the risks and uncertainties to which we are subject and for additional information regarding forward-looking statements.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,

         (212) 362-1200, stephanie@sternir.com

         Martina Schwarzkopf, Ph.D., Russo Partners,

         (212) 845-4292, martina.schwarzkopf@russopartnersllc.com

         Tony Russo, Ph.D., Russo Partners,

         (212) 845-4251, tony.russo@russopartnersllc.com
Source: Endocyte, Inc.

News Provided by Acquire Media